Home » EMEA Designates Preliminary Review Panel for Advanced Therapies
EMEA Designates Preliminary Review Panel for Advanced Therapies
February 17, 2009
The European Medicines Agency (EMEA) is turning to a new panel of experts to review gene- or cell-based treatments before the Committee for Medicinal Products for Human Use (CHMP) decides whether to recommend approval.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor